W M Kast

Title: W M Kast: Innovator in Cancer Immunotherapy

Introduction

W M Kast is a notable inventor based in Leiden, Netherlands, recognized for his contributions to cancer immunotherapy. He holds three patents, focusing on the development of peptides derived from tumor rejection antigen precursor MAGE-2. His work has significant implications for the treatment of cancer through immunological approaches.

Latest Patents

Kast's latest patents include isolated tumor rejection antigen precursor MAGE-2 derived peptides. These peptides are designed to bind with HLA-A2 molecules, creating complexes that stimulate the production of cytolytic T cells (CTLs). The CTLs generated are specific to the complexes formed by HLA-A2 and the peptide. This innovation can be utilized to produce monoclonal antibodies, and the cytolytic T cells may be applied in immunotherapy contexts, such as adoptive transfer.

Career Highlights

Throughout his career, W M Kast has worked with prestigious organizations, including the Ludwig Institute for Cancer Research Limited and the University of Leiden. His research has significantly advanced the understanding of tumor immunology and the development of targeted cancer therapies.

Collaborations

Kast has collaborated with esteemed colleagues, including Cornelis J Melief and Pierre Van Der Bruggen. These partnerships have fostered innovative research and development in the field of cancer immunotherapy.

Conclusion

W M Kast's contributions to the field of cancer immunotherapy through his patented innovations highlight the importance of targeted treatments in modern medicine. His work continues to inspire advancements in the fight against cancer.